Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
Show more...
首席执行官
Mr. Marcus Larsson Ph.D.
员工
4
国家
Sweden
上市
0 Comments
分享你的想法
FAQ
Amniotics AB 今天的股价是多少?▼
AMNI.ST 当前价格为 SEK0.01 SEK,过去 24 小时上涨了 +5.88%。在图表上更密切关注 Amniotics AB 股价表现。
Amniotics AB 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Amniotics AB 的股票以代码 AMNI.ST 进行交易。